Core Viewpoint - Skye Bioscience, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the company's lead product candidate, nimacimab, was less effective than previously represented, leading to overstated clinical, regulatory, and commercial prospects [2]. - Defendants are accused of making materially false and misleading public statements regarding the effectiveness and prospects of nimacimab [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Skye Bioscience, Inc. related to misrepresentation of the company's product effectiveness and prospects [1][2]. Group 1: Legal Investigation - Kuehn Law is looking into whether Skye Bioscience's insiders misrepresented the effectiveness of nimacimab, leading to overstated clinical, regulatory, and commercial prospects [2]. - The investigation is prompted by a federal securities lawsuit alleging that public statements made by Skye Bioscience were materially false and misleading [2]. Group 2: Shareholder Participation - Shareholders who purchased SKYE shares prior to November 4, 2024, are encouraged to contact Kuehn Law to enforce their rights, as there may be limited time to act [3]. - Kuehn Law covers all case costs and does not charge its investor clients, emphasizing the importance of shareholder involvement in maintaining market integrity [4].

Core Points - The Gross Law Firm has issued a notice to shareholders of Skye Bioscience, Inc. regarding a class action lawsuit related to misleading statements about the company's lead product candidate, nimacimab [1] - The class period for the lawsuit is from November 4, 2024, to October 3, 2025, during which it is alleged that the effectiveness of nimacimab was overstated [1] - Shareholders are encouraged to register for the class action by January 16, 2026, to potentially become lead plaintiffs and receive updates on the case [2] Allegations - The complaint alleges that Skye Bioscience's management made materially false and misleading statements about nimacimab's effectiveness [1] - It is claimed that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to inflated stock prices [1] Next Steps for Shareholders - Shareholders who purchased SKYE shares during the specified class period can register to be included in the case and will receive status updates through portfolio monitoring software [2] - There is no cost or obligation for shareholders to participate in the class action [2] About the Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company [3] - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [3] Group 3: Case Allegations - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the company's business and prospects [4] - Specific claims include that nimacimab was less effective than represented, leading to overstated clinical and commercial prospects [4] - The lawsuit asserts that when the true information became public, investors suffered damages [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to allegations of misleading statements related to the company's lead product candidate, nimacimab [1]. Group 1: Allegations and Class Period - The class period for the allegations is from November 4, 2024, to October 3, 2025 [1]. - The complaint alleges that the defendants made materially false and/or misleading statements about nimacimab, claiming it was more effective than it actually is [1]. - It is stated that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to misleading public statements [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by January 16, 2026, to potentially be appointed as lead plaintiff [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Insights - After-hours trading in the U.S. saw significant gains in small-cap and micro-cap biotech stocks, driven by a mix of catalyst-driven moves and sentiment-based rebounds following the Fed's rate cut Group 1: Notable After-Hours Gainers - Agape ATP Corp. (ATPC) surged 29.41% after hours to $0.088, despite no specific news, reflecting a broader risk-on sentiment in micro-cap stocks [1] - Corbus Pharmaceuticals Holdings, Inc. (CRBP) rose 12.76% after hours to $11.57, driven by anticipation of a key clinical update on its Phase 1a study of CRB-913 [2] - Anebulo Pharmaceuticals, Inc. (ANEB) increased 8.37% after hours to $2.33, aligning with the overall positive sentiment in small-cap biotech [3] - Cue Biopharma, Inc. (CUE) gained 13.12% after hours to $0.54, with no new developments, indicating a macro-driven recovery in biotech [4] - Curis, Inc. (CRIS) saw a 7.68% increase after hours to $1.3999, following positive clinical data presented at the ASH Annual Meeting [5] - Skye Bioscience, Inc. (SKYE) rose 7.02% after hours to $1.22, benefiting from the overall biotech market lift [6] - Cerus Corporation (CERS) increased 3.17% after hours to $1.95, continuing its upward trend after announcing a purchasing agreement with Blood Centers of America [7]

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that the defendants made false statements regarding the effectiveness of the Company's lead product candidate, nimacimab, which was claimed to be less effective than represented [2]. - It is asserted that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to materially false and misleading public statements by the defendants [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, nimacimab [1][3]. Group 1: Allegations - The complaint alleges that during the class period from November 4, 2024, to October 3, 2025, the defendants issued materially false and misleading statements regarding nimacimab's effectiveness [3]. - It is claimed that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to inflated public statements by the defendants [3]. Group 2: Shareholder Actions - Shareholders who purchased shares of SKYE during the specified class period are encouraged to register for the class action, with a deadline set for January 16, 2026 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [5].

Core Viewpoint - Skye Bioscience, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its lead product candidate, nimacimab, which was claimed to be less effective than represented [1][2]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 4, 2024, to October 3, 2025 [1]. - Allegations include that the company overstated the clinical, regulatory, and commercial prospects of nimacimab, leading to materially false and misleading public statements [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares during the class period are encouraged to register for the class action by January 16, 2026, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].

Core Viewpoint - Skye Bioscience, Inc. is facing legal action from investors following the failure of its clinical trial for nimacimab, which did not meet its primary endpoint for weight loss compared to placebo [4]. Group 1: Legal Action - A lawsuit has been filed against Skye Bioscience, Inc. by an investor alleging violations of securities laws, claiming that the company made false or misleading statements regarding the effectiveness of nimacimab [4]. - Investors who purchased over $100,000 in Skye Bioscience shares between November 4, 2024, and October 3, 2025, have a deadline of January 16, 2026, to take action [2]. Group 2: Clinical Trial Details - Skye Bioscience initiated the "CBeyond" clinical trial in August 2024, a 26-week study aimed at assessing nimacimab for obesity treatment, with a primary endpoint of an 8% difference in mean weight loss compared to placebo [3]. - On October 6, 2025, the company announced that the nimacimab monotherapy did not achieve the primary endpoint of weight loss compared to placebo, and preliminary analysis indicated lower than expected drug exposure [4].